Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants

Armin Spök; Richard M. Twyman; Rainer Fischer; Julian K.C. Ma; Penelope A.C. Sparrow

doi:10.1016/j.tibtech.2008.05.007

Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants

Armin Spök^*, Richard M. Twyman, Rainer Fischer, Julian K.C. Ma, Penelope A.C. Sparrow

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

Abstract

The use of genetically modified (GM) plants to synthesize proteins that are subsequently processed, regulated and sold as pharmaceuticals challenges two very different established regulatory frameworks, one concerning GM plants and the other covering the development of biotechnology-derived drugs. Within these regulatory systems, specific regulations and guidelines for plant-made pharmaceuticals (PMPs) - also referred to as plant-derived pharmaceuticals (PDPs) - are still evolving. The products nearing commercial viability will ultimately help to road test and fine-tune these regulations, and might help to reduce regulatory uncertainties. In this review, we summarize the current state of regulations in different countries, discuss recent changes and highlight the need for further regulatory development in this burgeoning, new industry. We also make the case for the harmonization of international regulations.

Original language	English
Pages (from-to)	506-517
Number of pages	12
Journal	Trends in Biotechnology
Volume	26
Issue number	9
DOIs	https://doi.org/10.1016/j.tibtech.2008.05.007
Publication status	Published - 1 Sept 2008

ASJC Scopus subject areas

Biotechnology
Bioengineering

Access to Document

10.1016/j.tibtech.2008.05.007

Cite this

@article{12f3f77b42cd43cf8ee7a8b1f54b17d0,

title = "Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants",

abstract = "The use of genetically modified (GM) plants to synthesize proteins that are subsequently processed, regulated and sold as pharmaceuticals challenges two very different established regulatory frameworks, one concerning GM plants and the other covering the development of biotechnology-derived drugs. Within these regulatory systems, specific regulations and guidelines for plant-made pharmaceuticals (PMPs) - also referred to as plant-derived pharmaceuticals (PDPs) - are still evolving. The products nearing commercial viability will ultimately help to road test and fine-tune these regulations, and might help to reduce regulatory uncertainties. In this review, we summarize the current state of regulations in different countries, discuss recent changes and highlight the need for further regulatory development in this burgeoning, new industry. We also make the case for the harmonization of international regulations.",

author = "Armin Sp{\"o}k and Twyman, {Richard M.} and Rainer Fischer and Ma, {Julian K.C.} and Sparrow, {Penelope A.C.}",

year = "2008",

month = sep,

day = "1",

doi = "10.1016/j.tibtech.2008.05.007",

language = "English",

volume = "26",

pages = "506--517",

journal = "Trends in Biotechnology",

issn = "0167-7799",

publisher = "Elsevier Limited",

number = "9",

}

TY - JOUR

T1 - Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants

AU - Spök, Armin

AU - Twyman, Richard M.

AU - Fischer, Rainer

AU - Ma, Julian K.C.

AU - Sparrow, Penelope A.C.

PY - 2008/9/1

Y1 - 2008/9/1

N2 - The use of genetically modified (GM) plants to synthesize proteins that are subsequently processed, regulated and sold as pharmaceuticals challenges two very different established regulatory frameworks, one concerning GM plants and the other covering the development of biotechnology-derived drugs. Within these regulatory systems, specific regulations and guidelines for plant-made pharmaceuticals (PMPs) - also referred to as plant-derived pharmaceuticals (PDPs) - are still evolving. The products nearing commercial viability will ultimately help to road test and fine-tune these regulations, and might help to reduce regulatory uncertainties. In this review, we summarize the current state of regulations in different countries, discuss recent changes and highlight the need for further regulatory development in this burgeoning, new industry. We also make the case for the harmonization of international regulations.

AB - The use of genetically modified (GM) plants to synthesize proteins that are subsequently processed, regulated and sold as pharmaceuticals challenges two very different established regulatory frameworks, one concerning GM plants and the other covering the development of biotechnology-derived drugs. Within these regulatory systems, specific regulations and guidelines for plant-made pharmaceuticals (PMPs) - also referred to as plant-derived pharmaceuticals (PDPs) - are still evolving. The products nearing commercial viability will ultimately help to road test and fine-tune these regulations, and might help to reduce regulatory uncertainties. In this review, we summarize the current state of regulations in different countries, discuss recent changes and highlight the need for further regulatory development in this burgeoning, new industry. We also make the case for the harmonization of international regulations.

UR - http://www.scopus.com/inward/record.url?scp=48849103075&partnerID=8YFLogxK

U2 - 10.1016/j.tibtech.2008.05.007

DO - 10.1016/j.tibtech.2008.05.007

M3 - Review article

C2 - 18676047

AN - SCOPUS:48849103075

SN - 0167-7799

VL - 26

SP - 506

EP - 517

JO - Trends in Biotechnology

JF - Trends in Biotechnology

IS - 9

ER -

Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this